(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1739194

ナノ粒子受託製造の世界市場

Nanoparticle Contract Manufacturing

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.06円
ナノ粒子受託製造の世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ナノ粒子受託製造の世界市場は2030年までに40億米ドルに達する見込み

2024年に28億米ドルと推定されるナノ粒子受託製造の世界市場は、2024年から2030年にかけてCAGR 6.5%で成長し、2030年には40億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである金属ナノ粒子は、CAGR 6.9％を記録し、分析期間終了までに26億米ドルに達すると予想されます。脂質ナノ粒子セグメントの成長率は、分析期間でCAGR 5.3％と推定されます。

米国市場は7億2,420万米ドルと推定、中国はCAGR6.4％で成長すると予測

米国のナノ粒子受託製造市場は、2024年に7億2,420万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.4%で推移し、2030年には6億4,610万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.1%と5.5%と予測されています。欧州では、ドイツがCAGR 5.2%で成長すると予測されています。

世界のナノ粒子受託製造市場- 主要動向と促進要因のまとめ

ナノ粒子受託製造がバイオ医薬品および素材セクターで戦略的重要性を増している理由とは？

ナノ粒子受託製造は、医薬品、バイオテクノロジー、化粧品、先端材料など、ナノテクノロジーに基づく製品の開発と商品化において、重要なイネーブラーとなっています。ナノ粒子製剤はしばしば複雑な合成、精製、特性評価工程を必要とするため、これらの工程を専門の製造受託機関（CMO）にアウトソーシングすることで、多くのイノベーターが社内で不足している規模、規制との整合性、技術的専門知識を提供することができます。このようなパートナーシップにより、新興企業や学術スピンオフ企業、さらには大手製薬企業は、ハイエンドのナノ製造インフラへの資本支出を抑えながら、製品開発を加速させることができます。

バイオ医薬品分野では、ナノ粒子はドラッグデリバリーの媒体として、特にリポソーム製剤、mRNAデリバリー用の脂質ナノ粒子（LNP）、ポリマーベースのナノ懸濁液などでますます使用されるようになっています。溶解性の向上、送達ターゲットの絞り込み、放出の制御、生物学的障壁の迂回などの能力により、腫瘍学、ワクチン、中枢神経系薬物において不可欠なものとなっています。これらの製品の複雑さが増し、粒子径、形態、純度に関する規制が厳しくなったことで、受託製造業者はナノメディシンのサプライチェーンに不可欠な存在となっています。製薬だけでなく、食品、パーソナルケア、エレクトロニクスなどの業界も、GMPやISO基準の下で高精度のナノ粒子製造を行うCMOに依存しています。

技術プラットフォーム、品質システム、プロセスの最適化はどのようにCMOの能力を高めているのか？

ナノ粒子を専門とする受託製造業者は、マイクロ流体工学、高圧ホモジナイゼーション、乳化拡散、超臨界流体処理、溶媒蒸発などのスケーラブルで再現可能な合成技術に投資しています。これらの技術により、粒子径分布、ゼータ電位、カプセル化効率、薬物充填量を厳密に制御することができます。連続製造プラットフォームも、特に高スループット・ナノキャリア製造において、より優れた歩留まりの一貫性とプロセス検証のために採用されています。

CMOは動的光散乱（DLS）、走査型電子顕微鏡（SEM）、原子間力顕微鏡（AFM）、HPLCによる高度な粒子特性評価を提供しています。規制に準拠した品質管理システム（QMS）は、臨床および商業バッチのデータ完全性、ロットトレーサビリティ、無菌性保証を保証します。一部のCDMOはまた、製剤サービス、無菌充填仕上げ、コールドチェーン・ロジスティクスをナノ粒子製造サービスに統合し、ナノメディシン開発者にエンドツーエンドのソリューションを提供しています。このようなサービスのバンドルにより、スポンサーの調整負担と規制の複雑さが軽減されます。

ナノ粒子製造サービスの需要を促進している応用分野と顧客セグメントは？

特に抗がん剤、mRNA治療薬、遺伝子編集ツール、長時間作用型注射薬などのナノキャリアを開発している製薬企業やバイオテクノロジー企業が需要の大半を占めています。LNPベースのCOVID-19ワクチンの成功は、核酸デリバリー用のナノ粒子プラットフォームへの投資を加速させ、既存企業も新規参入企業も製造委託サポートを求めるようになりました。皮膚科薬や眼科薬も、バイオアベイラビリティとターゲティング精度を高めるためにナノ粒子を使用しています。

ヘルスケア以外では、化粧品業界が紫外線ろ過、抗老化活性剤、皮膚吸収促進剤にナノ粒子を使用しています。飲食品企業は、風味保持や栄養強化のためにナノカプセル化を模索しています。エレクトロニクスとエネルギーの企業は、規模やコンプライアンス要件は異なるもの、バッテリー、コーティング、導電性インクにナノ粒子ソリューションを必要としています。新興企業や学術研究所は、パイロット・スケールの実施、実現可能性研究、規制文書化においてCMOに依存することが多いです。ナノ粒子を利用した製品が多様化するにつれて、専門的で垂直統合型のCMOに対する需要は増加の一途をたどっています。

ナノ粒子受託製造市場の長期的成長と差別化の原動力は？

ナノ粒子受託製造市場の成長の原動力は、ナノ化製品の普及、バイオテクノロジーの技術革新の加速、複雑で資本集約的なプロセスのアウトソーシング志向の高まりです。医薬品開発企業とCDMOの戦略的提携により、市場投入までの時間が短縮され、開発パイプラインのリスクが軽減され、競争が激化する治療領域において規制との整合性が確保されつつあります。ナノメディシン研究への政府資金援助、ナノ粒子ベースの治療薬に対する希少疾病用医薬品の指定、個別化ナノ治療薬への関心の高まりにより、需要は強化されています。

市場の差別化は、独自の技術プラットフォーム、規制に関する専門知識、初期段階と商業規模の両方の生産をサポートする能力を通じて行われています。ナノ粒子のIPを共同開発し、製剤のカスタマイズを提供し、世界の規制の枠組みに対応できるCMOは、特に有利な立場にあります。今後の動向としては、グリーンケミストリー・アプローチの拡大、機械学習主導のプロセス・モデリング、ナノスケール生産に合わせたモジュール式クリーンルーム設備などが挙げられます。ナノ粒子が産業全体のイノベーションの基礎となるにつれ、受託製造業者は、科学的可能性を商業的に実行可能な製品に転換する上で、ますます戦略的な役割を果たすようになると思われます。

セグメント

ナノ粒子の種類（金属ナノ粒子、脂質ナノ粒子、その他の種類のナノ粒子）、製造規模（商業製造規模、臨床製造規模、前臨床製造規模）、用途（治療薬用途、診断薬用途、ワクチン用途）、最終用途（製薬企業最終用途、バイオテクノロジー企業最終用途）

調査対象企業の例（全32件）

  • American Elements
  • Ardena Holding NV
  • Ascendia Pharmaceuticals
  • AstraZeneca
  • AVANSA Technology & Services
  • BBI Solutions（Novacyt Group）
  • BioVectra Inc.
  • CordenPharma International GmbH
  • Cytodiagnostics Inc.
  • Encapsula NanoSciences LLC
  • Evonik Industries AG
  • Fortis Life Sciences
  • FUJIFILM Corporation
  • LSNE Contract Manufacturing
  • Merck KGaA
  • MyBiotech GmbH
  • Nano Labs Corporation
  • nanoComposix, Inc.
  • Nanoscale Corporation
  • Nanoshel LLC

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP34111

Global Nanoparticle Contract Manufacturing Market to Reach US$4.0 Billion by 2030

The global market for Nanoparticle Contract Manufacturing estimated at US$2.8 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Metal Nanoparticles, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Lipid Nanoparticles segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$724.2 Million While China is Forecast to Grow at 6.4% CAGR

The Nanoparticle Contract Manufacturing market in the U.S. is estimated at US$724.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$646.1 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Nanoparticle Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Nanoparticle Contract Manufacturing Gaining Strategic Importance Across the Biopharma and Materials Sectors?

Nanoparticle contract manufacturing has become a critical enabler in the development and commercialization of nanotechnology-based products across pharmaceuticals, biotechnology, cosmetics, and advanced materials. As nanoparticle formulations often require complex synthesis, purification, and characterization steps, outsourcing these processes to specialized contract manufacturing organizations (CMOs) provides scale, regulatory alignment, and technical expertise that many innovators lack in-house. These partnerships allow startups, academic spin-offs, and even large pharma players to accelerate product development while reducing capital expenditure on high-end nano fabrication infrastructure.

In the biopharmaceutical sector, nanoparticles are increasingly used as drug delivery vehicles-particularly in liposomal formulations, lipid nanoparticles (LNPs) for mRNA delivery, and polymer-based nanosuspensions. Their ability to enhance solubility, target delivery, control release, and bypass biological barriers has made them indispensable in oncology, vaccines, and CNS drugs. The rising complexity of these products, coupled with tight regulatory controls around particle size, morphology, and purity, has made contract manufacturers integral to the nanomedicine supply chain. Beyond pharma, industries like food, personal care, and electronics also rely on CMOs for high-precision nanoparticle production under GMP and ISO standards.

How Are Technology Platforms, Quality Systems, and Process Optimization Enhancing CMO Capabilities?

Contract manufacturers specializing in nanoparticles are investing in scalable and reproducible synthesis technologies such as microfluidics, high-pressure homogenization, emulsion-diffusion, supercritical fluid processing, and solvent evaporation. These techniques allow tight control over particle size distribution, zeta potential, encapsulation efficiency, and drug loading-key metrics for regulatory success and therapeutic performance. Continuous manufacturing platforms are also being adopted for better yield consistency and process validation, especially in high-throughput nanocarrier production.

Robust analytical capabilities are a differentiator in this space, with CMOs offering advanced particle characterization via dynamic light scattering (DLS), scanning electron microscopy (SEM), atomic force microscopy (AFM), and HPLC. Regulatory-compliant quality management systems (QMS) ensure data integrity, lot traceability, and sterility assurance for clinical and commercial batches. Some CDMOs are also integrating formulation services, aseptic fill-finish, and cold chain logistics into their nanoparticle manufacturing offerings, delivering an end-to-end solution for nanomedicine developers. This bundling of services reduces the coordination burden and regulatory complexity for sponsors.

Which Application Areas and Client Segments Are Fueling Demand for Nanoparticle Manufacturing Services?

Pharmaceutical and biotech companies account for the majority of demand, particularly those developing nanocarriers for anticancer drugs, mRNA therapeutics, gene editing tools, and long-acting injectables. The success of LNP-based COVID-19 vaccines has accelerated investment in nanoparticle platforms for nucleic acid delivery, prompting both established players and new entrants to seek contract manufacturing support. Dermatological and ophthalmic drugs are also using nanoparticles to enhance bioavailability and targeting precision.

Outside healthcare, the cosmetics industry uses nanoparticles for UV filtration, anti-aging actives, and skin absorption enhancers. Food and beverage companies are exploring nano-encapsulation for flavor preservation and nutrient fortification. Electronics and energy firms require nanoparticle solutions for batteries, coatings, and conductive inks, albeit at different scales and compliance requirements. Startups and academic labs often rely on CMOs for pilot-scale runs, feasibility studies, and regulatory documentation. As nanoparticle-enabled products diversify, demand for specialized and vertically integrated CMOs continues to grow.

What Is Driving Long-Term Growth and Differentiation in the Nanoparticle Contract Manufacturing Market?

The growth in the nanoparticle contract manufacturing market is driven by the proliferation of nano-enabled products, accelerated biotech innovation, and increasing preference for outsourcing complex and capital-intensive processes. Strategic collaborations between drug developers and CDMOs are reducing time-to-market, de-risking development pipelines, and ensuring regulatory alignment in increasingly competitive therapeutic areas. Demand is being reinforced by government funding for nanomedicine research, orphan drug designations for nanoparticle-based therapies, and rising interest in personalized nanotherapeutics.

Market differentiation is occurring through proprietary technology platforms, regulatory expertise, and the ability to support both early-phase and commercial-scale production. CMOs that can co-develop nanoparticle IP, offer formulation customization, and navigate global regulatory frameworks are especially well-positioned. Future trends include the expansion of green chemistry approaches, machine learning-driven process modeling, and modular cleanroom facilities tailored for nano-scale production. As nanoparticles become foundational to innovation across industries, contract manufacturers will play an increasingly strategic role in converting scientific potential into commercially viable products.

SCOPE OF STUDY:

The report analyzes the Nanoparticle Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type of Nanoparticles (Metal Nanoparticles, Lipid Nanoparticles, Other Types of Nanoparticles); Manufacturing Scale (Commercial Manufacturing Scale, Clinical Manufacturing Scale, Pre-clinical Manufacturing Scale); Application (Therapeutics Application, Diagnostics Application, Vaccines Application); End-Use (Pharmaceutical Companies End-Use, Biotechnology Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • American Elements
  • Ardena Holding NV
  • Ascendia Pharmaceuticals
  • AstraZeneca
  • AVANSA Technology & Services
  • BBI Solutions (Novacyt Group)
  • BioVectra Inc.
  • CordenPharma International GmbH
  • Cytodiagnostics Inc.
  • Encapsula NanoSciences LLC
  • Evonik Industries AG
  • Fortis Life Sciences
  • FUJIFILM Corporation
  • LSNE Contract Manufacturing
  • Merck KGaA
  • MyBiotech GmbH
  • Nano Labs Corporation
  • nanoComposix, Inc.
  • Nanoscale Corporation
  • Nanoshel LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Nanoparticle Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Nanomedicine Pipelines Drives Demand for Specialized Contract Manufacturing Services
    • Rise in Targeted Drug Delivery Systems Spurs Adoption of Nanoparticle Formulations
    • Expansion of mRNA and Nucleic Acid-Based Therapeutics Strengthens Business Case for Lipid Nanoparticles
    • Outsourcing Trend in Pharma and Biotech Boosts Demand for End-to-End Nanoparticle CDMO Solutions
    • Emergence of Personalized Nanomedicine Expands Addressable Market for Custom Particle Engineering
    • Increased Complexity in Regulatory Filings Throws the Spotlight on GMP-Compliant CDMOs
    • Collaborative Drug Development Models Propel Growth in Specialized Manufacturing Partnerships
    • Rapid Commercialization of RNA-Based Vaccines Drives Demand for Scalable Nanoparticle Production
    • Innovation in Polymer and Lipid Nanoparticles Enhances Customization Potential
    • Proliferation of Oncology Nanotherapeutics Fuels Growth in High-Precision Contract Manufacturing
    • Investment in Containment and Sterile Facilities Strengthens Capabilities of Leading CDMOs
    • Surging Need for Small-Batch Clinical Manufacturing Drives Flexibility in CDMO Offerings
    • Integration of Process Analytical Technology (PAT) Enables Real-Time Particle Size Control
    • Global Regulatory Harmonization Efforts Simplify Cross-Border Market Entry for Contract Manufacturers
    • Application of AI and ML in Process Design Supports Optimization and Cost Reduction
    • Increasing Use of Nanoparticles in Cosmetics and Nutraceuticals Broadens End-User Base
    • Establishment of Nano Innovation Hubs and Tech Transfer Centers Spurs Regional CDMO Expansion
    • Demand for Surface Functionalization Services Generates Differentiation Opportunities
    • Rising Emphasis on Sustainable Nanoparticle Synthesis Presents Greener Manufacturing Avenues
    • Shortage of Specialized Talent and Equipment Poses Scalability Challenges for Smaller CDMOs
    • Strategic Alliances Between Pharma Giants and Specialized CDMOs Propel Innovation in Delivery Platforms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nanoparticle Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nanoparticle Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Metal Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Metal Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Lipid Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Lipid Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Types of Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Types of Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Commercial Manufacturing Scale by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Commercial Manufacturing Scale by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Manufacturing Scale by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Clinical Manufacturing Scale by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pre-clinical Manufacturing Scale by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Pre-clinical Manufacturing Scale by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapeutics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Therapeutics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • JAPAN
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • CHINA
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • EUROPE
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • FRANCE
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • GERMANY
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030

IV. COMPETITION